Oxford BioTherapeutics' Corporate Minority Round

Oxford BioTherapeutics raised a round of funding on May 18, 2009. Investors include GlaxoSmithKline.

Oxford BioTherapeutics is an international, clinical-stage biotechnology company focused on developing antibody-based therapies to treat cancer. Combining immuno-oncology, antibody-drug conjugates, an…

Articles about Oxford BioTherapeutics' Corporate Minority Round: